Search Results for "retail"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for retail. Results 131 to 140 of 361 total matches.
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 17, 2014 (Issue 1436)
by FDB, Inc. All rights
reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy.
Actual retail ...
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist approved for PAH. It is a derivative
of bosentan (Tracleer), which is also manufactured
by Actelion, and is scheduled to become available generically
in 2015. Riociguat (Adempas), another new drug for
this indication, will be reviewed in a future issue.
Volibris
Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD
The Medical Letter on Drugs and Therapeutics • Apr 14, 2014 (Issue 1440)
. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.
2. Only the 250/50 mcg strength ...
The FDA has approved an inhaled fixed-dose
combination of the long-acting anticholinergic
umeclidinium (ue mek" li din' ee um) and the long-acting
beta2-adrenergic agonist (LABA) vilanterol
(Anoro Ellipta – GSK/Theravance) for once-daily
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Anoro Ellipta is the first
product available in the US that combines two long-acting
bronchodilators in a single delivery device.
Sublingual Immunotherapy for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
. All rights reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices ...
The FDA has approved 3 allergen extracts for sublingual
administration as immunotherapy for allergic rhinitis
confirmed by a positive skin test or in vitro testing for
pollen-specific IgE antibodies: Oralair (Stallergenes
S.A./Greer) and Grastek (Merck) for grass pollen-induced
allergic rhinitis and Ragwitek (Merck) for short
ragweed pollen-induced allergic rhinitis.
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Jun 23, 2014 (Issue 1445)
. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.
3. Doses ...
The FDA has approved another solution of the
aminoglycoside antibiotic tobramycin (Bethkis –
Chiesi/Cornerstone) for oral inhalation via a nebulizer
for management of cystic fibrosis (CF) patients with
Pseudomonas aeruginosa.
Luliconazole Cream (Luzu) for Tinea Infections
The Medical Letter on Drugs and Therapeutics • Jun 23, 2014 (Issue 1445)
, Inc. All rights
reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices ...
The FDA has approved luliconazole (Luzu Cream, 1% –
Valeant) for treatment of tinea pedis, tinea cruris, and
tinea corporis infections.
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
retail prices may be higher.
2. Zontivity is available as 2.5-mg vorapaxar sulfate tablets, equivalent ...
The FDA has approved vorapaxar (Zontivity – Merck), an
oral protease-activated receptor-1 (PAR-1) antagonist,
for use with aspirin and/or clopidogrel to reduce the risk
of thrombotic cardiovascular events in patients with
peripheral arterial disease or a history of myocardial
infarction (MI). It is the first PAR-1 antagonist to be
approved by the FDA.
Efinaconazole Topical Solution (Jublia) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail
prices may be higher.
3. Dosage adjustment ...
The FDA has approved efinaconazole 10% solution
(Jublia – Valeant) for topical treatment of toenail
onychomycosis due to Trichophyton rubrum and/or
Trichophyton mentagrophytes. It is the first topical
triazole antifungal drug to be approved for this
indication. A topical oxaborole antifungal solution,
tavaborole 5% (Kerydin – Anacor), also recently
approved by the FDA for the same indication will be
reviewed in a future issue.
An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
to Sandoz, Symjepi will be made available
first to institutions and later to the retail market ...
The FDA has approved a manually
injected, single-dose, prefilled
epinephrine syringe (Symjepi –
Adamis/Sandoz) for emergency
treatment of anaphylaxis. The new
device is approved in 0.3- and
0.15-mg strengths for treatment of
patients weighing ≥30 kg and 15 to
30 kg, respectively; only the 0.3-mg
strength is currently available.
According to Sandoz, Symjepi will be made available
first to institutions and later to the retail market.
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
January 12, 2025. Individual retailers may have their own generic products.
3. Dosage adjustments ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721f | Show Introduction Hide Introduction
Colesevelam (Welchol) For Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • Oct 30, 2000 (Issue 1091)
based on AWP listings in Drug Topics Red Book Update,October 2000. Retail prices may be higher or lower ...
Colesevelam hydrochloride (Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary hypercholesterolemia.